Telmisartan Hydrochlorothiazide Tablets

Not yet clear.

Telmisartan 80 mg, hydrochlorothiazide 12.5 mg

This product is an oval double-layer tablet, one layer is white or off-white, and the other layer is red.

Used to treat essential hypertension.

1. Adults: For adult patients whose blood pressure cannot be adequately controlled with telmisartan alone, this product can be given once a day with drinking water, before or after meals. It is recommended to titrate the doses of the two components in the compound preparation separately before switching to the compound preparation. If the condition is appropriate, it is also possible to consider converting telmisartan monotherapy directly to the compound preparation. For patients whose blood pressure cannot be adequately controlled with telmisartan 80 mg, telmisartan hydrochlorothiazide tablets 80/12.5 mg can be given for treatment. 2. Medication for renal impairment: It is recommended to monitor renal function regularly. 3. Medication for liver impairment: For patients with mild to moderate liver impairment, the dosage should not exceed telmisartan hydrochlorothiazide tablets 40/12.5 mg, once a day. For patients with severe liver function

1. In a foreign randomized controlled trial, the overall incidence of adverse events reported was similar between the telmisartan hydrochlorothiazide tablets treatment group and the telmisartan monotherapy group. A total of 1,471 patients were included in the randomized controlled trial, of which 835 received telmisartan hydrochlorothiazide treatment and 636 received telmisartan monotherapy. The dose-related relationship of adverse events has not been determined, and there is no correlation between adverse events and gender, age and race. 2. Adverse reactions reported in all clinical trials with an incidence that was significantly higher in the telmisartan hydrochlorothiazide treatment group than in the placebo treatment group (p≤0.05) are listed in the table below according to system organ classification. It is known that one of the components of the telmisartan hydrochlorothiazide tablets, telmisartan or hydrochlorothiazide, will occur when administered alone, but it has not been shown in clinical trials.

1. Patients who are allergic to other sulfonamide derivatives are prohibited from using this product; 2. Patients in the second trimester and third trimester of pregnancy and during lactation are prohibited from using this product; 3. Patients with cholestatic diseases and biliary obstructive diseases are prohibited from using this product; 4. Patients with severe liver damage are prohibited from using this product; 5. Patients with severe renal damage are prohibited from using this product; 6. Patients with refractory hypokalemia and hypercalcemia are prohibited from using this product; 7. Patients in the middle and late stages of pregnancy and during lactation are prohibited from using this product; 8. Patients with biliary obstructive diseases are prohibited from using this product; 9. Patients with severe liver dysfunction are prohibited from using this product; 10.

Precautions for children: Use in children and adolescents: The safety and effectiveness of Telmisartan Hydrochlorothiazide Tablets in children and adolescents up to 18 years of age have not been established. Precautions for pregnancy and lactation: Pregnant and lactating women are prohibited. Precautions for the elderly: The pharmacokinetic properties of Telmisartan do not differ between elderly patients and patients under 65 years of age. No dose adjustment is required.

1. Lithium: There are reports showing that a reversible increase in serum lithium ion concentration and toxic reactions may occur during the combined use of lithium and angiotensin-converting enzyme inhibitors. In very rare cases, the above situation has also been observed during the combined use of lithium and angiotensin II receptor antagonists. In addition, thiazide diuretics can lead to a decrease in the renal clearance of lithium. As a result, the risk of lithium toxicity when lithium is used in combination with telmisartan hydrochlorothiazide tablets is also increased accordingly. Therefore, lithium and telmisartan hydrochlorothiazide tablets can only be used in combination under strict medical monitoring, but the combination of the two is not recommended. If combined use is necessary, it is recommended to monitor serum lithium ion levels during the combined use. Drugs associated with potassium loss and hypokalemia (such as other potassium-excreting diuretics, laxatives, corticosteroids, adrenocorticotropic hormone, amphotericin

Seal and store in a dry place at room temperature.

Each tablet contains 40 mg of telmisartan and 12.5 mg of hydrochlorothiazide

24 months

Suzhou Chung- HWA Chemical & Pharmaceutical Industrial Co., Ltd.

• Founded in:

  1993-04-27

• Address:

  No. 66, Yong'an Road, Suzhou High-tech Zone

• Tax NO.:

  913205056081966464

• Registered Funds:

  $25.5 million

• Website:

  Log in to view

• Email:

  Log in to view